AB
CADL icon

Amalgamated Bank’s Candel Therapeutics CADL Stock Holding History

Amalgamated Bank’s Portfolio CADL Stock Details CADL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,377
Closed -$8K – 1822
2025
Q4 		$8K Buy
1,377
+397
+41% +$2.14K ﹤0.01% 2505
2025
Q3 		$5K Hold
980
– – ﹤0.01% 2742
2025
Q2 		$5K Hold
980
– – ﹤0.01% 2720
2025
Q1 		$6K Buy
980
+294
+43% +$2.4K ﹤0.01% 2567
2024
Q4 		$6K Hold
686
– – ﹤0.01% 2647
2024
Q3 		$5K Hold
686
– – ﹤0.01% 2742
2024
Q2 		$4K Buy
+686
New +$5.15K ﹤0.01% 2831

Other funds holding CADL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Amalgamated Bank's CADL Position: Q1 2026 in Review

Amalgamated Bank sold out of Candel Therapeutics (CADL) in Q1 2026, closing a stake of 1,377 shares — an estimated $8K sold.

Amalgamated Bank first reported a position in CADL in Q2 2024 and held it in 7 quarters. The position peaked at $8K in Q4 2025. 114 funds tracked by Wall St. Rank hold CADL as of Q1 2026.

  • Amalgamated Bank reported no remaining Candel Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Amalgamated Bank sold 1,377 Candel Therapeutics shares in Q1 2026, an estimated $8K.
  • Amalgamated Bank first reported a position in Candel Therapeutics in Q2 2024 and held it in 7 quarters.
  • Amalgamated Bank's Candel Therapeutics position peaked at $8K in Q4 2025.
  • 114 funds tracked by Wall St. Rank held Candel Therapeutics as of Q1 2026.

Based on Amalgamated Bank's 13F filing for Q1 2026, filed 8 May 2026.